Latest Breaking News On - Josephine belluardo - Page 6 : comparemela.com

Nanotechnology Now - Press Release: Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress

Nanotechnology Now - Press Release: Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress

Nanotechnology Now - Press Release: Arrowhead Pharmaceuticals to Participate in Upcoming Conferences

Sio Gene Therapies Announces CSF Reductions in GM1 Ganglioside from Clinical Trial of AXO-AAV-GM1 Gene Therapy

Nanotechnology Now - Press Release: Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease

Home > Press > Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease Abstract: Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim 48-week liver biopsy results from the AROAAT2002 study, an open-label Phase 2 clinical study of ARO-AAT, the company’s second generation investigational RNA interference (RNAi) therapeutic being co-developed with Takeda Pharmaceutical Company Limited ( Takeda”) as a treatment for the rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD). The results demonstrate that ARO-AAT treatment led to a consistent and substantial reduction in intra-hepatic mutant AAT protein (Z-AAT), both Z-AAT monomer and Z-AAT polymer; a consistent decrease in histological globule burden; improvements in fibrosis; and, improvements in other relevant biomarkers of liver health. Arrowhead intends to present additional interim AROAAT2002 data at an upcoming medical congress